Characteristics, goal‐oriented treatments and survival of pulmonary arterial hypertension in China: Insights from a national multicentre prospective registry

• Published in: Respirology (Carlton, Vic.) Vic.), 2022-07, Vol.27 (7), p.517-528
• Main Authors: Quan, Ruilin, Zhang, Gangcheng, Yu, Zaixin, Zhang, Caojin, Yang, Zhenwen, Tian, Hongyan, Yang, Yuanhua, Wu, Weifeng, Chen, Yucheng, Liu, Yuhao, Zhu, Xianyang, Li, Shengqing, Shen, Jieyan, Zheng, Zeqi, Zhu, Xiulong, Wang, Guangyi, Wang, Qian, Zhou, Daxin, Ji, Yingqun, Yang, Tao, Li, Wen, Chen, Xiaoxi, Qian, Yuling, Lin, Yangyi, Gu, Qing, Xiong, Changming, Shan, Guangliang, He, Jianguo
• Format: Article
• Language: English
• Subjects: Chinese multicentre prospective registry; Coronary artery disease; Developing countries; Heart diseases; Hypertension; LDCs; Patients; pulmonary arterial hypertension; Pulmonary hypertension; Respiratory diseases; Risk assessment; risk stratification; Survival; treatment
• ISSN: 1323-7799; 1440-1843
• DOI: 10.1111/resp.14247

Background and objective Nationally representative reports on the characteristics and long‐term survival of pulmonary arterial hypertension (PAH) from developing countries are scarce. The applicability of the current main risk stratifications and the longitudinal changes in goal‐oriented treatments have yet to be elucidated in real‐world settings. Therefore, we aimed to provide insights into the characteristics, goal‐oriented treatments and survival of PAH in China and to explore the applicability of the main risk stratifications in our independent cohort. Methods PAH patients were consecutively enrolled from a national prospective multicentre registry. Data on baseline, follow‐up re‐evaluation and therapeutic changes were collected. Results A total of 2031 patients were enrolled, with congenital heart disease (CHD)‐PAH (45.2%) being the most common aetiology. The mean age was 35 ± 12 years, and 76.2% were females. At baseline, approximately 20% of the patients with intermediate or high risk received combination treatment. At follow‐up, approximately half of the re‐evaluated patients did not achieve low‐risk profiles, and even among patients who received combination therapy at baseline, 4% of them still worsened. The rate of combination therapy increased significantly from 6.7% before 2015 to 35.5% thereafter. The main risk assessment tools demonstrated good performance for predicting survival both at baseline and at follow‐up. Conclusion Chinese PAH patients show both similar and distinct features compared to other countries. Current main risk stratifications can significantly discriminate patients at different risk levels. There were still many patients not achieving low‐risk profiles at follow‐up, indicating more aggressive treatment should be implemented to optimize the goal‐oriented treatment strategy. This Chinese registry study revealed that Chinese patients with pulmonary arterial hypertension showed both similar and distinct features compared to other countries. Many patients did not achieve low‐risk profiles at follow‐up, indicating more aggressive treatment should be implemented to optimize goal‐oriented therapy for these patients.